Where to Get Retatrutide UK | Cured Pharmacy Guide

Clinically Proven UK Registered Pharmacy

Where to Get Retatrutide Peptide in the UK

UK-registered clinical team
Confidential and secure
No GP visit needed
Fast and discreet delivery
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £10 off for new customers
Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment
£145.00 From £135.00 £10 discount using discount code Weightlossnew
LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen - UK-licensed prescription Treatment
Treatment

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From £145.00

Future orders save 5%
Start Assessment
Wegovy (Semaglutide) Weight Loss Injection - UK-licensed prescription Treatment
Treatment

Wegovy (Semaglutide) Weight Loss Injection

From £89.00

Future orders save 5%
Start Assessment
Saxenda - UK-licensed prescription Treatment
Treatment

Saxenda

From £68.00

Future orders save 5%
Start Assessment
Orlistat - UK-licensed prescription Treatment
Treatment

Orlistat

From £32.00

Future orders save 5%
Start Assessment
Xenical Orlistat 120mg Capsules - UK-licensed prescription Treatment
Treatment

Xenical Orlistat 120mg Capsules

From £49.99

Future orders save 5%
Start Assessment
Wegovy® Oral Tablets (Semaglutide Pill): PRE-ORDER - UK-licensed prescription Treatment
Treatment

Wegovy® Oral Tablets (Semaglutide Pill): PRE-ORDER

From £83.00

Future orders save 5%
Start Assessment

Understanding Retatrutide UK Availability and Licensed Alternatives

If you're searching for retatrutide UK options, it's important to understand that retatrutide is currently in clinical trials and not yet licensed by the MHRA for prescription use in the United Kingdom. However, proven alternatives with similar mechanisms—including tirzepatide (Mounjaro) and semaglutide (Wegovy)—are available through UK-registered pharmacies like Cured Pharmacy, offering significant weight loss outcomes backed by extensive clinical evidence.

What Is Retatrutide and Why Isn't It Available in the UK Yet?

Retatrutide is an investigational triple agonist peptide that activates GIP, GLP-1, and glucagon receptors simultaneously [1]. This three-pathway approach represents the next generation of metabolic therapies, building on the success of dual agonists like tirzepatide. In Phase 2 trials, participants achieved average weight reductions of up to 24.2% over 48 weeks, making it one of the most promising obesity treatments in development [1].

Currently, retatrutide UK availability is limited to clinical trial participation, as it has not yet received MHRA licensing for general prescription use. The medication is undergoing Phase 3 trials globally, with regulatory approval anticipated in 2025 or beyond. Until then, UK patients seeking advanced weight loss peptides can access licensed alternatives that work through similar biological pathways [2].

Licensed Retatrutide UK Alternatives: Mounjaro and Wegovy

While awaiting retatrutide UK approval, two MHRA-licensed medications offer comparable mechanisms and proven efficacy. Mounjaro (tirzepatide) is the UK's only dual GIP/GLP-1 receptor agonist, activating two of the three pathways that retatrutide targets [3]. In the SURPASS-2 trial, patients achieved an average 22.5% body weight reduction over 72 weeks—results that rival early retatrutide data [3].

Wegovy (semaglutide) works through selective GLP-1 receptor activation and demonstrated average weight loss of 14.9% in the STEP-1 trial [4]. Both treatments are administered as once-weekly subcutaneous injections and require clinical assessment by a UK prescriber before dispensing. At Cured Pharmacy, Mounjaro starts from £135.00 following a free online consultation with our UK-registered clinical team.

How These Alternatives Compare to Retatrutide

The key difference lies in receptor activation: retatrutide targets three pathways (GIP, GLP-1, glucagon), tirzepatide targets two (GIP, GLP-1), and semaglutide targets one (GLP-1). More pathways generally correlate with greater metabolic effects, but licensed dual and single agonists already deliver clinically significant outcomes. Your UK prescriber will recommend the most appropriate treatment based on your medical history, weight loss goals, and contraindications.

Retatrutide UK Clinical Trials: What the Evidence Shows

The Phase 2 trial published in The New England Journal of Medicine enrolled 338 adults with obesity across multiple international sites [1]. Participants receiving the highest retatrutide dose (12 mg weekly) lost an average of 24.2% of their baseline body weight over 48 weeks, compared to 2.1% in the placebo group. Importantly, 91% of participants in the highest-dose group achieved at least 5% weight loss, and 75% achieved at least 15% weight loss [1].

Common side effects mirrored those of other incretin-based therapies: nausea (60-70% of participants), diarrhoea, vomiting, and constipation, predominantly mild to moderate in severity [1]. Serious adverse events were rare and comparable across groups. These safety profiles informed the ongoing Phase 3 programme, which will determine whether retatrutide UK licensing proceeds.

Treatment Active Ingredient Administration Starting Price
Mounjaro Tirzepatide (dual agonist) Once-weekly injection From £145.00
Wegovy Semaglutide (GLP-1 agonist) Once-weekly injection From £89.00
Saxenda Liraglutide (GLP-1 agonist) Daily injection From £68.00
Orlistat Orlistat (lipase inhibitor) Three times daily capsule From £32.00
Xenical Orlistat 120mg (lipase inhibitor) Three times daily capsule From £49.99

Why Choose Cured Pharmacy for Weight Loss Treatments

As a GPhC-registered online pharmacy (registration number 9012511), Cured Pharmacy dispenses only genuine UK-licensed medications under the supervision of our superintendent pharmacist, Tarun Kumar (GPhC 2233073). Every prescription treatment—including Mounjaro, Wegovy, and Saxenda—requires clinical assessment by a UK-registered prescriber, ensuring safe, personalised care that meets MHRA standards.

We offer transparent upfront pricing with no hidden consultation fees, 100% discreet packaging, and next-day delivery across the UK. Our online assessment takes under three minutes to complete, and you'll receive a clinical decision within hours. If approved, your medication is dispensed from our UK pharmacy and delivered directly to your door.

Our Weight Loss Treatment Range

Beyond injectable GLP-1 therapies, we stock oral weight loss aids including Orlistat (from £135.00), Xenical, and Alli capsules. These lipase inhibitors work by reducing dietary fat absorption and are suitable for patients who prefer tablet-based treatments. Your prescriber will discuss all licensed options during your consultation to identify the most effective approach for your individual circumstances.

How to Start Your Weight Loss Journey at Cured Pharmacy

Begin by completing our free online consultation, which gathers essential medical history including current medications, allergies, cardiovascular health, and previous weight loss attempts. A UK-registered prescriber reviews your assessment within hours and determines whether injectable or oral treatments are clinically appropriate. If Mounjaro or Wegovy is prescribed, you'll receive dosing instructions, injection technique guidance, and information on managing potential side effects.

Treatment typically starts at the lowest maintenance dose to minimise gastrointestinal symptoms, with gradual titration over 16-20 weeks as tolerated. Regular follow-up assessments monitor your progress, adjust dosing, and ensure ongoing suitability. Most patients begin noticing appetite reduction within the first week, with measurable weight loss evident by week four [3][4].

Retatrutide UK: Future Availability and What to Expect

Phase 3 trials for retatrutide are currently recruiting participants worldwide, with results expected by late 2025. If these trials replicate Phase 2 efficacy and safety outcomes, the manufacturer will submit regulatory applications to the MHRA, FDA, and EMA. UK licensing timelines typically extend 12-18 months beyond application submission, meaning widespread retatrutide UK availability may not occur until 2026 or 2027 [2].

Until then, patients seeking the most advanced licensed weight loss therapies can access tirzepatide through Cured Pharmacy. As a dual agonist, Mounjaro represents the current pinnacle of incretin-based treatment in the UK, offering superior outcomes to single-pathway medications while maintaining an acceptable safety profile. Our clinical team stays updated on emerging therapies and will offer retatrutide as soon as MHRA licensing is granted.

Staying Informed About New Treatments

We recommend subscribing to updates from Cured Pharmacy to receive notifications when retatrutide or other novel weight loss medications receive UK approval. In the meantime, our pharmacists are available at (+44) 116 4646009 to discuss current treatment options, answer questions about clinical trials, and provide evidence-based guidance on achieving sustainable weight loss with licensed therapies.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2023). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
  2. Medicines and Healthcare products Regulatory Agency. (2024). Clinical Trials Guidance: Obesity Treatments. GOV.UK. https://www.gov.uk/guidance/clinical-trials-for-medicines
  3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
  4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Retatrutide is not currently licensed by the MHRA for use in the UK.

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Can I buy retatrutide UK online from Cured Pharmacy?
Retatrutide is not yet licensed by the MHRA for prescription use in the UK. It remains in Phase 3 clinical trials, with regulatory approval anticipated in 2025 or later. Cured Pharmacy stocks licensed alternatives including Mounjaro (tirzepatide) and Wegovy (semaglutide).
What is retatrutide UK availability timeline?
Retatrutide UK licensing depends on Phase 3 trial outcomes and subsequent MHRA review, likely making it available for prescription by 2026-2027. Until then, dual-agonist tirzepatide offers the most advanced licensed mechanism.
How does retatrutide compare to Mounjaro?
Retatrutide activates three receptors (GIP, GLP-1, glucagon) versus Mounjaro's two (GIP, GLP-1). Phase 2 retatrutide data showed 24.2% average weight loss compared to Mounjaro's 22.5% in SURPASS trials, though direct head-to-head comparisons have not been conducted.
Is retatrutide UK legal to import privately?
Importing unlicensed medications for personal use exists in a legal grey area and carries significant risks including counterfeit products, incorrect dosing, and lack of clinical oversight. We strongly recommend using MHRA-licensed alternatives through registered UK pharmacies.
What are the side effects of retatrutide UK trials?
Phase 2 trials reported nausea (60-70%), diarrhoea, vomiting, and constipation as the most common side effects, similar to other GLP-1 therapies. Most were mild to moderate and decreased over time with continued treatment.
Can I join a retatrutide UK clinical trial?
Phase 3 retatrutide trials are recruiting globally. Visit clinicaltrials.gov and search 'retatrutide obesity' to find UK trial sites. Participation requires meeting specific eligibility criteria and involves regular monitoring visits.
How much will retatrutide cost in the UK when licensed?
Pricing for retatrutide UK has not been announced. Based on current GLP-1 therapy pricing, expect costs comparable to or higher than Mounjaro. NHS availability will depend on NICE appraisal following MHRA licensing.
What is the best alternative to retatrutide available now in the UK?
Mounjaro (tirzepatide) is the closest licensed alternative, offering dual GIP/GLP-1 agonism with average weight loss of 22.5% in clinical trials. It's available from Cured Pharmacy from £135.00 following clinical assessment by a UK prescriber.